Blood Cancer Sector More Competitive After Keytruda Approval
Executive Summary
The US FDA approval of Keytruda in its first hematologic cancer indication will put Merck & Co in a position to compete with Bristol-Myers Squibb, whose own checkpoint inhibitor Opdivo gained a similar, but not identical, marketing approval in classical Hodgkin lymphoma last year.
You may also be interested in...
CHMP Opinions: Opdivo Sees Keytruda's Hodgkin's And Raises It Head & Neck
Merck & Co and Bristol Myers Squibb's rival anti-PD1 products continue their game of one-upmanship with each gaining a new indication in the latest round of EU CHMP opinions.
Keeping Track: US FDA Clears Kisqali For Breast Cancer And Keytruda In Lymphoma, But Turns Down AZ's ZS-9 Again
The latest drug development news and highlights from our FDA Performance Tracker.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.